/
Oncology
Advanced Solid Tumours
23
Pipeline Programs↗
27
Active Trials↗
30
Companies Involved↗
Advanced Solid Tumours is an emerging landscape with 23 programs across 30 companies. The most active players are LaNova Medicines Limited, Suzhou BlueHorse Therapeutics Co., Ltd., Hangzhou Hanx Biopharmaceuticals, Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
LPhase 2SPhase 1HPhase 2
Phase 2MPhase 1SPhase 1
LaNova Medicines Limited
2 programs
Suzhou BlueHorse Therapeutics Co., Ltd.
2 programs
Hangzhou Hanx Biopharmaceuticals, Ltd.
1 program
Orion Corporation, Orion Pharma
1 program
Multitude Therapeutics (Australia) Pty Ltd
1 program
Suzhou Forlong Biotechnology Co., Ltd
1 program
Pipeline
Programs by Phase
Preclinical
No programs
Phase 111
Phase 212
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
18 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.
Analysis
Trial Status
103
clinical trials
Completed58 · 56%
Recruiting20 · 19%
Terminated12 · 12%
Unknown status6 · 6%
Not yet recruiting4 · 4%
Active, not recruiting3 · 3%
Clinical Trials
Trial Activity
103 trials
A Study of EBC-129 in Advanced Solid Tumours
Recruiting·EEDDC (Experimental Drug Development Centre), A*STAR Research Entities·Phase 1·NCT05701527·98 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)